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Background: Improving vitamin D (25-OHD) status may be an important modifiable factor that could reduce
disability severity, fall-rates and mortality associated after hip fracture surgery. Providing a loading-dose post-surgery
may overcome limitations in adherence to daily supplementation.
Method: In this randomized, double-blind, placebo-controlled trial, 218 adults, aged 65-years or older, requiring
hip fracture surgery were assigned to receive a single loading-dose of cholecalciferol (250,000 IU vitamin-D3, the
REVITAHIP - Replenishment of Vitamin D in Hip Fracture strategy) or placebo, both receiving daily vitamin-D(800 IU)
and calcium (500 mg) for 26-weeks. Outcome measures were 2.4 m gait-velocity, falls, fractures, death (Week-4),
25-OHD levels, quality-of-life measure (EuroQoL) and mortality at weeks-2, 4 and 26.
Results: Mean age of 218 participants was 83.9(7.2) years and 77.1 % were women. Baseline mean 25-OHD was
52.7(23.5)nmol/L, with higher levels at Week-2 (73 vs 66 nmol/L; p = .019) and Week-4 (83 vs 75 nmol/L; p = .030)
in the Active-group, but not at Week-26. At week-4, there were no differences in 2.4 m gait-velocity (0.42 m/s vs
0.39 m/s, p = .490), fractures (2.7 % vs 2.8 %, p = .964) but Active participants reported less falls (6.3 % vs 21.1 %,
χ2 = 4.327; p = 0.024), with no significant reduction in deaths at week-4 (1 vs 3, p = 0.295), higher percentage
reporting ‘no pain or discomfort’ (96.4 % vs 88.8 %, p = 0.037), and trended for higher EuroQoL-scores (p = 0.092) at
week-26. One case of hypercalcemia at week-2 normalised by week-4.
Conclusion: Among older people after hip fracture surgery, the REVITAHIP strategy is a safe and low cost method of
improving vitamin-D levels, reducing falls and pain levels.
Trial registration: The protocol for this study is registered with the Australian New Zealand Clinical Trials Registry
ANZCTRN ACTRN12610000392066 (Date of registration: 14/05/2010).
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Hip fractures and related disabilities are important
public health issues for older people around the world
[1–6]. Despite the age-adjusted hip fracture rates re-
ducing in countries such as Australia and the United
States, the actual numbers of fractures are increasing
steadily due to the increasing proportion of the elderly
population. By 2040, an estimated 512,000 hip fractures* Correspondence: jenson.mak@gmail.com
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billion per year, [2] and by 2050, an estimated 76.7 billion
Euros will be spent on this problem in Europe [3].
Outcomes for people who survive hip fracture are of
concern, with more than one-quarter dying within a
two-year period [7], and most not recovering their
previous level of function [4, 5]. More than 10 % of
survivors will be unable to return to their previous
residence. Most of the remainder will have some re-
sidual pain or disability [6]. Given that people require
assistance to recover from a hip fracture, personal
and societal costs are often incurred following surgery
due to the need for rehabilitation, outpatient visits forle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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facility placement if required, and assistance with ac-
tivities of daily living at home during the recovery
period [8]. Given these factors, the quest in improv-
ing function after a hip fracture has the potential to
be of enormous benefit to elderly people by reducing
disability and improving quality of life. This can then
reduce direct treatment costs and costs of long-term
community or residential aged care services. The abil-
ity to mobilise is the key activity underlying function-
ing and quality of life [9].
Hypovitaminosis D is commonly associated with hip
fracture in older people. It occurs because of several
factors including decreased sun exposure with re-
duced skin production of vitamin D and low dietary
D2/D3 intake. Vitamin D replacement, mostly with
calcium, has been used successfully to reduce such
fractures, as well as falls among older people [10–12].
Without preventive treatment, however, hypovitami-
nosis D following hip fracture may result in proximal
muscle weakness, pain, reduced dynamic balance and
performance speed, [13] affecting mobilization during
the acute postoperative and rehabilitation periods
[14–16]. This study assessed the efficacy and safety of
a loading dose of cholecalciferol for the improvement
of gait velocity, 25-hydroxycholecalciferol (25-OHD)
levels, falls, fractures, functional outcomes and mortality
in women and men who had undergone recent surgical
repair of a hip fracture over a 26 week period.Methods
Study design
The Replenishment of Vitamin D in Patients with Hip
Fracture (REVITAHIP) Trial was a multicenter, random-
ized, double-blind, placebo-controlled trial involving pa-
tients with recent hip fracture [17]. Patients were
randomly assigned to receive either an oral loading dose
of cholecalciferol (at a dose of 250,000 IU vitamin D3)
or placebo, both receiving daily supplementation with oral
vitamin D (800 IU) and calcium (500 mg).1 Deviation
from this protocol occurred for two participants (one in
each group) with an initial serum 25-hydroxyvitamin D
level of 10 nmol/L or less due to the known risks. These
cases received an additional 14-day loading dose of vita-
min D3 (at a dose of 4000 IU given orally), continuing on
as per other patients for the remainder of the trial.
Patients were monitored for up to 26 weeks with
telephone interviews or clinic/home visits at 2, 4, 12 (tele-
phone interview only) and 26 weeks. All study procedures
were approved by the local institutional review board
(Northern Sydney Local Health District (NSLHD) - HREC
Number 10/ HARBR/14). The study is registered with
both the Australian Clinical Trial Registry (ACTR No.12610000392066). This research was carried out in com-
pliance with the Helsinki Declaration.
The academic investigators initiated the concept of the
study. A data and safety monitoring board consisting of
site investigators and the chief investigator met quarterly
to oversee the conduct and safety of the study. Data ana-
lysis was performed by a statistician at the Office of
Medical Education, Sydney Medical School, University
of Sydney, New South Wales, Australia.Patients
All patients who were enrolled in the trial had under-
gone hip fracture surgery at one of three hospitals in
Sydney and the Central Coast, New South Wales,
Australia [17, 18]. They were invited to participate if
they were aged 65 years or over and able to provide in-
formed consent, either directly or via the person legally
responsible for making decisions on their behalf, were
deemed suitable by the treating medical team, and were
able to take a loading dose of vitamin D within seven
days after surgery [17]. Patients with delirium or demen-
tia were included only after consent had been obtained
from both the patient and the legal surrogate. The mo-
bility and functional status of participants have been pre-
viously reported [18].
Exclusion criteria were: being bed-bound prior to
fracture, or having a life expectancy deemed less than
1 month by the treating clinical staff; hypercalcemia
(serum calcium >2.65 mmol/L); history of nephro-
lithiasis; thyrotoxicosis; Paget’s disease; sarcoidosis;
malignancy (except skin cancer) and associated patho-
logical fractures; significant renal impairment (serum
creatinine >0.15 mmol/L); liver disease (alanine ami-
notransferase or aspartate aminotransferase level >2
times the upper limit of the normal range); undergo-
ing treatment with calcitriol, or already undergoing
treatment with > =1000 IU daily oral vitamin D3.
Mean (SD) age of participants was 83.9 (7.2) years and
77.1 % were women. Most participants (81.7 %) were
born in Australia and 93.6 % spoke English as the first
language. Approximately 83 % of participants had a pre-
injury residence in the community, with 44 % living
alone [18].Randomization and blinding
Patients were randomly assigned to treatment groups at
a central location, accessed through a central telephone
number and using a computer-generated random num-
ber schedule with variable block sizes of 2 to 6. Study
patients, investigators, steering committee members, and
faculty who adjudicated the clinical and safety end
points remained unaware of study-group assignments
throughout the trial.
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The primary outcome measure was gait velocity over 2.4 m
[19] and was measured at weeks 2, 4, and 26, with baseline
assumed to be 0 immediately following surgery. Secondary
outcome measures were the number of falls, fractures and
hospitalizations, activities of daily living (using the Barthel
Index [20]), quality of life (EQ5D [Euroqol] [21]), 25-OHD
and calcium levels, grip strength, adherence to calcium and
vitamin D supplements, and adverse events (including car-
diovascular events and death).Assessment of outcomes (Table 1)
Falls were recorded at 2 and 4 weeks using calendars
where participants lived in the community, or using resi-
dential aged care facility or hospital records where par-
ticipants were in care. A fall was defined according to
the Kellogg definition [22] as an incident in which the
body unintentionally comes to rest on the ground or
other lower level which was not as a result of a violent
blow, loss of consciousness, and sudden onset of paralysis
as in a stroke or an epileptic seizure. Where a fall was re-
corded, determination according to this definition would
follow via interview with the patient or their carer.
Fractures and hospitalizations (measured at 2 and
4 weeks) were recorded by the participants if living in
the community or by care facility records and were veri-
fied by contact with the participant’s general practitioner
or hospital. Quality of life was assessed at 4, 12 and
26 weeks using the EQ5D, a valid and reliable measure
of quality of life in older people [21]. 25-OHD levels
were determined using the DiaSorin assay [23] from the
same laboratory for the three sites and measured at initial
assessment, 2, 4, and 26 weeks. Grip strength in kilograms
was assessed at initial assessment, 2, 4, and 26 weeks using
a portable dynamometer (JAMAR hydraulic Hand Dyna-
mometer manufactured by Sammons Prestons: Access
Health. Unit 1 Rear, 194–196 Whitehorse Rd, BLACK-
BURN VIC 3130 Australia). Calcium/vitamin D adherence
was recorded at initial assessment, 2, 4, 12 and 26 weeks
by participants or their carer if living in the community or
confirmed by care facility records. Rate of adherence wasTable 1 REVITAHIP Outcome Measures
Outcome Measure Time Measurement
2.4 m gait-velocity Baseline, Weeks 2, 4
Grip strength Baseline, Weeks 2, 4
Falls Baseline, Weeks 2, 4
Fractures Baseline, Weeks 2, 4
Mortality Baseline, Weeks 2, 4
25-OHD levels Baseline, Weeks 2, 4, 26
Quality-of-life measure (EuroQoL) Baseline, Weeks 2, 4, 12, 26expressed as a percentage of doses taken up to each meas-
urement point.
Adverse events and laboratory measures
The site investigator reported adverse events and serious
adverse events at each measurement point. Such events
were categorized with the use of the Medical Dictionary
for Regulatory Activities [24]. The expert committee
whose members were unaware of the study-group as-
signment adjudicated laboratory criteria, adverse events
and primary cause of death.
Statistical analysis
Calculations were based on statistical power of 80 %
with the alpha set at .05 (2-sided test). To address the
primary hypothesis of the study, a sample size of 125 per
group was initially estimated to show a 10 % difference
in mean gait velocity improvement at the 4-week follow-
up assessment. The number of 250 was not recruited
due to feasibility of funding of 218 participants. Data
were coded to permit blinding to group allocation in the
initial statistical analysis. Differences in the primary out-
come measure between the two groups over time were
analyzed using repeat-measures analysis of variance
(GLM in IBM SPSS version 21.0). Separate analyses
assessing change over time relative to baseline were per-
formed at each follow-up point to maximize use of the
data available. Mean gait velocity change scores relative
to baseline at weeks 2, 4 and 26 follow up, as well as be-
tween follow-up points, were calculated. Similar methods
were used for secondary outcomes where data were con-
tinuous. Pearson chi-square test was used where outcome
measures were categorical, supplemented with use of Fish-
er’s exact Chi square test when cell counts were small.
Missing data at week 2 were imputed for one case with
otherwise complete data using the within case mean of
baseline and week 4 data. Imputation of missing data at
other follow up points was not possible. Analyses followed
the intention-to-treat principle. The study protocol speci-
fied that a 25-OHD assay be performed prior to the load-
ing dose. However, despite requests prior to the loading
dose, in 62 (28.4 %) cases the 25-OHD assay was con-
ducted within 24–48 hours after the loading dose. These
62 participants were excluded from analyses using base-
line 25-OHD as an independent or dependent variable.
These 62 participants were, however, included in all other
analyses. Logistic regression was used to determine the
odds ratio for having a fall within the study period.
Results
Baseline characteristics and follow-up (Table 2)
Of a total of 218 patients, 111 patients were randomly
assigned to receive loading dose cholecalciferol (Active)
and 107 patients were assigned to receive placebo; 74.1 %
Table 2 Summary Baseline Demographic and Clinical Characteristics of REVITAHIP Participantsa
Variables Active (n = 111) Placebo (n = 107) P value
Sex – n (%)
- Female 84 (75.7) 84 (78.5) 0.633
- Male 27 (24.3) 23 (21.5)
Country of Birth – n (%)
- Australia 92 (82.9) 86 (80.4) 0.727
- Other 19 (17.1) 21 (19.6)
Age
Mean (years)b 83.7+/−7.5 84.1+/−7.0 0.726
Grouped – n (%)
- 65-74 yr 15 (13.5) 10 (9.3) 0.772
- 75-84 yr 43 (38.7) 42 (39.3)
- 85-94 yr 47 (42.3) 50 (46.7)
- 95+ yr 6 (5.4) 5 (4.7)
Body mass index (kg/m2)b 24.2+/−3.4 25.1+/−3.8 0.099
Number of days from admission to loading doseb 4.8+/−2.1 5.4+/−2.3 0.049
Pre-injury mobility – n (%)d
- Fully independent 80 (72.1) 72 (67.9) 0.156
- Minimum help 15 (13.5) 15 (14.2)
- Moderately help 8 (7.2) 7 (6.6)
- Substantial help 1 (0.9) 8 (7.5)
- Unable to perform task 7(6.3) 4(3.8)
Pre-injury Modified Barthel index 87.5+/−19.9 86.9+/−22.2 0.852
Pre-injury Functional Comorbidity Index b 3.37+/−2.1 2.9+/−1.7 0.063
Hip Fracture Subtype – n (%)d
- Undisplaced subcapital 6 (5.7) 3 (2.8) 0.442
- Displaced subcapital: 50 (47.2) 48 (45.3)
- Pertrochanteric simple (2-part) 5 (4.7) 5 (4.7)
- Pertrochanteric complex (3-part) 27 (25.5) 34 (21.1)
- Intertrochanteric/basicervical 5 (4.7) 9 (8.5)
- Subtrochanteric 13 (12.3) 7 (6.6)
Time from fracture to surgery (in hours)b 43.8+/−38.9 38.9+/−25.9 0.272
Hip Fracture Surgeryd 0.655
- Cannulated screws 4 (3.7) 1 (0.9)
- Uncemented hemiarthroplasty 15 (14.0) 14 (13.2)
- Cemented hemiarthroplasty 8 (7.5) 9 (8.5)
- Total hip replacement 19 (17.8) 20 (18.9)
- Dynamic hip screw with short plate 14 (13.1) 8 (7.5)
- Dynamic hip screw with long plate 19 (17.8) 20 (18.9)
- Gamma nail 28 (26.2) 34 (32.1)
MMSE score (mean, standard deviation)b 26.32+/−4.3 25.7+/−4.4 0.282
Total number of medications usedb 5.1+/−2.6 4.9+/−2.6 0.201
25-hydroxyvitamin D level (nmol/L)c
Mean 55.6+/−26.4 49.6+/−19.7 0.112
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Table 2 Summary Baseline Demographic and Clinical Characteristics of REVITAHIP Participantsa (Continued)
Grouped values: n (%)e
- <30 13 (16.5) 11 (14.3) 0.621
- 30-49 22 (27.8) 27 (35.1)
- > = 50 44 (55.7) 39 (50.6)
Grip strength (kgs)b 16.4+/−7.3 15.7+/−6.2 0.478
aPlus-minus values are means +/− SD
bContinuous variables were compared with the use of a two-sample t-test. Categorical variables were compared with the use of a chi-square test
cFor participants given the intervention loading dose after 25-OHD levels were taken (n = 156), (Placebo = 77; Active = 79)
dThe following categories contained missing variables: hip fracture subtype (6 missing, n = 212), hip fracture surgery (6 missing, n = 212), premorbid mobility (1
missing, n = 217)
eNowson CA, McGrath JJ, Ebeling PR, Haikerwal A, Daly RM, Sanders KM, Seibel MJ, Mason RS; Working Group of Australian and New Zealand Bone and Mineral
Society, Endocrine Society of Australia and Osteoporosis Australia. Vitamin D and health in adults in Australia and New Zealand: a position statement. Med J Aust.
2012;196(11):686–7 [25]
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successfully followed up to primary outcome at week
4 (Fig. 1). The median follow-up time was 24.8 weeks.
Overall 18 % of participants were lost to follow-up,
predominantly due to an inability to contact patients
by phone for assessment. The rate of loss was similarFig. 1 Enrolment and Flow of the Patients from REVITAHIPin the two groups. The percentage of patients who re-
ported adherence of at least 80 % or better to vitamin
D and calcium supplements was 95.7 % at week 4,
95.9 % at week 12 and 96.3 % at week 26. Adherence
did not differ significantly between the groups at any
assessment point.
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tics did not differ significantly between the two group
with three exceptions. A higher percentage of the Ac-
tive group reported comorbid diabetes (25.2 % vs 9.4 %;
p = 0.002) and depression (21.6 % vs 8.5 %; p = 0.008)
compared to the Placebo group. Also time from admission
to loading dose was marginally less in the Active group
than the Placebo group (4.8 vs 5.4 days, p = 0.049). The
most common coexisting medical conditions in this
population at baseline were arthritis, osteoporosis,
upper gastrointestinal disease, visual impairment and
diabetes [18].
Gait velocity
Mean 2.4 m gait velocity at weeks 2, 4 and 26, as well as
change scores between assessment points, are shown in
Table 3. Patients across both groups showed consistent sig-
nificant improvements over time. As expected, at week 4
both groups increased significantly in mean gait velocity to
a combined mean of 0.404+/−0.30 m/s from a baseline of 0
(p = 0.000). However, there were no significant differences
between the groups in improvements over time. Specifically,
mean improvement in gait velocity at 4 weeks from baseline
in the Active group was 0.419+/−0.295 m/s compared with
0.389+/−0.325 m/s in the Placebo groups (p = 0.490).
25-hydroxyvitamin D (25-OHD) levels (Fig. 2)
For patients in which 25-OHD levels were assessed
prior to the intervention loading dose (n = 156), mean 25-
OHD was 52.7+/−23.5 mmol/L (median = 54.2). Hypovita-
minosis D (<50 nmol/L) was present in 46.8 % of these
participants. Vitamin D levels among participants have
been reported in an earlier paper where it was noted that
15.4 % of participants had levels <30 nmol/L and only 2
participants had levels <10 nmol/L.(36) Among these 156
participants there was a significantly higher percentage
with adequate 25-OHD (> = 50 nmol/L) at week 4 (96.8 vs
84.6 %, p = 0.031) in the Active group when compared to
the Placebo group. At week 2 and week 4 mean 25-OHD
levels were significantly higher for the Active group versus
the Placebo group (at week 2, 72+/−20. vs 66+/−19 nmol,Table 3 Changes in gait velocity as a function of time and treatmen
Active N
Change in Gait Velocity
- Baseline to week 2 0.173 +/−0.259 107
- Baseline to week 4 0.419 +/−0.295 106
- Baseline to week 26 0.753 +/−0.264 83
- Week 2 to Week 4 0.250 +/−0.238 106
- Week 2 to Week 26 0.549 +/−0.307 83
- Week 4 to Week 26 0.316 +/−0.300 83
aSignificance level is shown for the time by group interaction (note for comparison
changes over time across both groups reached significance at p = 0.000p = 0.019; and at week 4, 80+/−20 vs 72+/−23 nmol/L,
p = 0.049), but not at week 26. However, the groups
did not differ significantly in the changes over the
time intervals from baseline to weeks 2, 4, or 26.Falls and fractures
A total of 44 new falls occurred in 30 patients by week
four. To week 4, seven (6.3 %) participants in the Active
group reported 1 or more falls compared to twenty-three
(21.1 %) in the Placebo group (χ2 = 4.327; p = 0.024). At
week 4, the Active group was associated with a falls rate of
250.0 (number of falls/days x 1000), as compared with
821.4 in the Placebo group; an absolute risk reduction of
57.1 % and a relative reduction of 69.6 % (Figs. 3 and 4).
The odds ratio of any fall, for the Placebo group in com-
parison to the Active group, within the first 4 weeks of the
study was 3.332 (CI: 1.340 to 8.235, p = 0.010). At week 4,
three (2.7 %) of participants in the Active group had 1 or
more fractures compared with 3 (2.8 %) in the Placebo
group (p = .964). The risk reduction was very similar in
the intention-to-treat and per-protocol populations. Fur-
ther, at week 2, there was trend for lower 25-OHD (65.4
vs 71.8 nmol/L, F = 3.669, p = 0.057) among participants
that fell, and at week 4, 25-OHD levels were significantly
lower for those that fell (70.0 vs 82.1 nmol/L, F = 10.458,
p = 0.001). There was a trend for statistical significance in
25-OHD concentrations between those who sustained a
fracture compared to those who did not at week 4 (70.4 vs
78.5 nmol/L, F = 2.781, p = 0.097).Function and quality of life
Among patients in the Active group, the mean Barthel
Index was 88.0+/−16.6, compared with 86.9+/−17.2
(p = 0.62) in the Placebo group at 4 weeks. Mean dif-
ferences in Barthel Index at 4 weeks from premorbid
functioning in the Active group was 0.55 compared
with 0.05 in the Placebo groups (p = 0.96). There
were no significant differences at each of the time
points between the groups. Further, regarding grip
strength, there were also no significant differencest group
Placebo n Significancea
0.155 +/−0.255 106 0.608
0.389 +/−0.325 104 0.490
0.738 +/−0.258 80 0.718
0.232 +/−0.249 104 0.582
0.568 +/−0.282 80 0.694
0.359 +/−0.356 80 0.404
s to baseline of 0, group and group by time interactions are identical). All
Fig. 2 Mean 25-hydroxyvitamin D levels over 26 weeks (* significance noted at Week 2 and 4)
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18.7+/−8.3kgs, F = .055, p = .815).
The health related quality of life data were as follows.
Overall, there was no significant difference in total Euro-
QoL at Week 4 but a higher total EuroQoL score was
noted for Active participants (88.1+/−13.2 vs 84.3+/−15.8,
F = 2.87, p = 0.092), although not significant. EuroQoL
subscales between the Active and Placebo groups were
similar at Week 4 or 26, except for the EuroQoL pain sub-
scale. Participants in the Active group were more likely to
have ‘no pain or discomfort’ at Week 26 following hip
fracture surgery (96.4 % vs 88.8 %, p = 0.037).Safety analysis
In the safety analysis, 4 of 218 patients (1.8 %) died during
the study, of whom 1 (0.9 %) were in the Active group and
3 (2.8 %) were in the Placebo group. The hazard ratio of
3.054 (95 % CI, 0.816 to 15.133; p = 0.295) indicated the
observed difference was not significant. The numbers of
death were small relating to a combination of cardiovascu-
lar morbidity, and sepsis-related morbidity. Due to the
small numbers there was an inability to detect a significant
difference. No serious adverse events occurred in the two
groups. One patient in the Active group (0.3 %) and no pa-
tient in the Placebo group had adjudicated hypercalcemia
(serum corrected calcium > 2.65 nmol/L). There were noFig. 3 Cumulative number of falls over 4 weeks (** denotes statistical diffesignificant differences in mean serum corrected calcium
levels at each of the assessment points.
Discussion
The REVITAHIP study has shown that in older patients fol-
lowing hip fracture surgery, a loading dose of 250,000 IU
vitamin D3 (“Active”) compared with Placebo, followed by
treatment with vitamin D (800 IU) and calcium (500 mg)
daily in both groups, resulted in higher 25-OHD levels and
a greater percentage with target ‘sufficient’ 25-OHD levels
(>50 nmol/L, [25, 26]), with no significant differences in gait
velocity at 4 weeks. A significantly reduced incidence of falls
but not fractures was noted in the Active group compared
with Placebo over four weeks. This is surprising because in
the study cohort the baseline level of 25-OHD was higher
than in other studies of patients with hip fracture [27].
Further, the differences in 25-OHD from initial measure-
ment to weeks 2 and 4 respectively between the Active and
Placebo groups, while significant, were not large.
Older patients with hip fracture experience increased
morbidity, functional decline, and death, as well as in-
creased use of health care services, and therefore repre-
sent an important population to investigate for advancing
improvements in quality of life and function, and the pre-
vention of falls and secondary fractures. Our study pro-
vides much needed data to help determine whether
vitamin D replenishment strategies are effective in suchrence)
Fig. 4 Fall, Fractures and Deaths over 4 weeks by Intervention Group (** denotes statistical difference)
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study were older and had more coexisting conditions and
a higher risk of falls than patients in many clinical trials of
treatment for osteoporosis, our findings contain helpful
information for clinicians and for patients who have had a
hip fracture.
Poor adherence to vitamin D therapy has been shown to
compromise the efficacy of this treatment for fracture re-
duction and, therefore, to increase medical costs [28].
Such findings have been particularly notable in frail older
adults [29]. Vitamin D deficiency is frequently observed in
older patients and is associated with an increased risk of
hypocalcemia when intravenous bisphosphonates are ad-
ministered before a normal vitamin D level has been
achieved [13]. Due to the very high rates of vitamin D de-
ficiency noted in the HORIZON Recurrent Fracture study
(observed in the first 385 patients [30]), the REVITAHIP
investigators adopted a similar loading dose vitamin D
followed by maintenance Vitamin D at 800 IU (and cal-
cium) daily supplied to the participants (with an overall
adherence of >80 %). The results were that almost all the
participants in the Active treatment group reached target
vitamin D (>50 nmol/L) at week 2 and 4 compared with
the Placebo group.
The Active group showed a non-significant lower mor-
tality rate compared with the Placebo group which is
likely related to the study being underpowered to detect
a difference, or due to random variation. However, from
results of the Dubbo Osteoporosis Study [1] that all low-
trauma fractures were associated with increased mortal-
ity risk for 5 to 10 years, and subsequent fracture was
associated with increased mortality risk for an additional
5 years, a significant reduction in falls and in the Active
REVITAHIP group is likely to confer a mortality reduc-
tion in this high-risk population. Further, data from a
large meta-analysis of eight prospective studies (26018
men and women) suggest those with vitamin D defi-
ciency (in the bottom quintile) were 1.57 times more
likely to die compared with those in the top quintiles.[31] Finally, there is a strong signal for mortality reduc-
tion from high-dose vitamin D in severely deficient ICU
patients in the hospital period but not 6 months, sug-
gesting the mortality reduction benefit is likely to be
within the first 21 days of administration [32].
The safety profile for high-dose loading dose of vita-
min D indicated few areas of concern, consistent with
previous findings [1]. There was one case of biochemical
hypercalcemia. We did not find an increased incidence
of renal adverse events. With the loading dose of
250,000 IU vitamin D in a group of subjects who had
already sustained a hip fracture, our findings contrast
with those of Sanders et al. who reported increased falls
and fractures following a loading dose of 500,000 IU in
healthy post-menopausal females [31].
An interesting point of discussion deserves mention.
Whilst there was a significant difference in the 25-OHD
levels between the Active and Placebo groups at the
early stages of rehabilitation (Week 2 and Week 4), it
was a surprise finding that a 6.3 and 7.7 nmol/L differ-
ence in these levels, with no difference in gait velocity
could translate into significant reductions in falls rates.
These results showed that the vitamin D levels did not in-
crease after 4 weeks even in the Active group with the
high dose of vitamin D. This might be because of the half-
life of serum 25- hydroxyvitamin D (normally 3 weeks) ac-
cording to Holick [33]. There was also a large effect with
falls reduction rate (relative reduction of 69.6 % at
Week 4) in the Active group compared with other
studies [34, 35]. However our results may have been a
chance finding or influenced by unidentified factors. Fi-
nally, there was a small but significant difference (0.6 days)
between the delivery of the loading-dose vitamin D such
that this was provided earlier in the Active compared to
the Placebo group. Possible explanations of this include
optimization of proximal muscle strength [14, 15] and dy-
namic balance parameters, [15] to enable earlier effective
rehabilitation. Our results suggest that other factors will
need further investigation in the future.
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tients were, on average, slightly younger and healthier
than are patients with hip fracture in the general
population (83 vs 84 years old), [36] as suggested by
data regarding 1-year mortality. However, patients in
our study ranged widely in age (up to 101 years), and
some had cognitive impairment. Perhaps due to inclusion
and exclusion criteria, there was under-recruitment of
people with very low 25-OHD levels compared to the
usual population with hip fractures due to the low number
of participants from residential aged care facility (10 %)
and participants with fewer total comorbidities. Our co-
hort of participants had relatively good function with
moderate independence prior to their hip fracture.
However, the investigators believe that this could also
be considered a strength as it alerts clinicians to poten-
tial problems (e.g. in ADLs, mobility, high psychotropic
medication use) even in a relatively well functioning co-
hort. Furthermore, it proved difficult to obtain an ac-
curate diary of falls from all participants over the
longer term. So falls data from weeks 12 and 26 could
not be included in the presentation of the data. Indeed,
our data contrasts with that from Vital-D study (which
showed increased falls and fractures in the first
3 months of the study) [37]. Whilst Vital-D had a lon-
ger follow-up period for falls (3 years vs 4 weeks), there
were vast differences in participant characteristics and
study protocol with REVITAHIP, with the former study
being (1) community-dwelling women only, (2) younger
population (age 74 versus 84, by 10 years), (3) partici-
pants given yearly higher boluses of 500,000 IU for
3 years, and (4) participants not provided with any
regular maintenance vitamin D/calcium therapy. Fur-
ther, a higher percentage of the Active group reported
comorbid diabetes compared to the Placebo group.
Whilst there is a higher association of patient groups
with osteoporosis who have diabetes, overall fracture
rates in the Active group did not show a significance
difference compared with the placebo group. Finally,
our participants had a higher level of baseline 25-OHD
compared to expected, likely owing to a less frail par-
ticipant population. There is still significant discussion
in the literature regarding the optimal 25OHD level for
benefit, and a number of reports suggest progressive
decline in fall risk at levels above 80 nmo/L [37],
whilst others recommended level of 60 nmo/L in
Summer [38]. Another limitation was that the planned
sample size of 250 could not be achieved due to time and
funding limitations in participant recruitment. Neverthe-
less, as 25-OHD levels in the REVITAHIP trial at baseline
were higher than usual concentrations, and all patients re-
ceived daily supplementation with vitamin D and calcium,
the trial may have underestimated effects on falls, frac-
tures and death. The rate of follow-up to final interviewwas lower than ideal at 74 %. Also, the length of follow-up
for mortality was short (4 weeks) compared to other stud-
ies which have a longer follow-up time (5–10 years)
[37]. It was the study team’s aim to complete a total
follow-up of 26 weeks, but this was not possible. How-
ever, there was no evidence of differential loss to
follow-up between the study groups. Next, the limited
number of participants (n = 62) who had 25-OHD level
measured prior to loading dose precluded a complete
examination of the true value of baseline 25-OHD
levels (leading to an over-estimation of 25-OHD levels
in the groups. However, our intention-to-treat analyses
on primary and secondary outcomes ensures that the
results are accurate and true to the ‘a priori' hypotheses
of the REVITAHIP study. Further, we understand that
the significant finding regarding pain would not main-
tain significance if strict correction for multiple out-
comes was undertaken (e.g. Bonferroni correction),
however, we believe that the results are best interpreted
for their clinical relevance and significance. Finally, the
inclusion of a history of falls and osteoporotic fractures
over the preceding 12 months, as well as a detailed
dietary history of calcium and vitamin D and the degree
of sun-exposure, parathyroid hormone levels and ana-
lyses examining their relationship with baseline vitamin
D status would have strengthened the study.
Conclusion
In conclusion, our findings indicate that treatment with
250000 IU cholecalciferol within 7 days after hip fracture
surgery is associated with higher percentage of replete
25-OHD, reduced rates of falls and reduced pain levels.
Given the relatively low expense of this intervention,
and beneficial impact on the burden of morbidity and
mortality from hip fracture, further evidence (in the
form of longitudinal safety studies) is required to con-
firm the findings of our study.
Endnote
1Since the protocol paper, there had been concerns re-
garding the safety of high-dose oral calcium supplements
on participants on cardiovascular morbidity and mortality
and thus the dosage of calcium was altered.
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